Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology Inc.    ZIOP

ZIOPHARM ONCOLOGY INC. (ZIOP)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

ZIOPHARM to Present at the Stifel 2017 Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CEST

BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Contact:
David Pitts
Argot Partners
212-600-1902
[email protected]


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIOPHARM ONCOLOGY INC.
06/21ZIOPHARM ONCOLOGY : Reports on Status of Investigational New Drug Application fo..
AQ
06/19ZIOPHARM ONCOLOGY : shares tumble after FDA places clinical hold on cancer trial
AQ
06/19ZIOPHARM ONCOLOGY : Reports on Status of Investigational New Drug Application fo..
AQ
06/19ZIOPHARM ONCOLOGY : Hold for upcoming point-of-care CAR T trial sinks Ziopharm s..
AQ
06/18ZIOPHARM ONCOLOGY INC : Shareholder Director Nominations, Other Events, Financia..
AQ
06/18Ziopharm Oncology Reports on Status of Investigational New Drug Application f..
GL
06/04Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Resp..
GL
05/17ZIOPHARM ONCOLOGY : Reports First Quarter 2018 Financial Results and Provides Co..
AQ
05/16Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 i..
GL
05/11ZIOPHARM ONCOLOGY, INC. (NASDAQ : ZIOP) Files An 8-K Results of Operations and F..
AQ
More news
News from SeekingAlpha
06/20Gene therapy players in the green 
06/19Ziopharm Gets Hit With Clinical Hold, Like All Other CAR-T Safety Precautions.. 
06/18Midday Gainers / Losers (06/18/2018) 
06/18HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (06/18/2018) 
06/18PREMARKET LOSERS AS OF 9 : 05 am (6/18/2018) 
Financials ($)
Sales 2018 3,59 M
EBIT 2018 -59,6 M
Net income 2018 -74,6 M
Finance 2018 71,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 107x
Capi. / Sales 2019 95,7x
Capitalization 454 M
Chart ZIOPHARM ONCOLOGY INC.
Duration : Period :
ZIOPHARM Oncology Inc. Technical Analysis Chart | ZIOP | US98973P1012 | 4-Traders
Technical analysis trends ZIOPHARM ONCOLOGY INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 6,58 $
Spread / Average Target 106%
EPS Revisions
Managers
NameTitle
Laurence James Neil Cooper Chief Executive Officer
David M. Mauney Chief Operating & Business Officer, Executive VP
Kevin G. Lafond Treasurer, Chief Accounting Officer & SVP-Finance
Francois Lebel Chief Medical Officer, EVP-Research & Development
Murray F. Brennan Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY INC.-22.95%454
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS6.23%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.32%9 557
SAREPTA THERAPEUTICS INC152.21%9 196